Roundview Capital LLC Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Roundview Capital LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 3.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,741 shares of the company’s stock after selling 2,140 shares during the quarter. Johnson & Johnson comprises 0.9% of Roundview Capital LLC’s portfolio, making the stock its 20th biggest holding. Roundview Capital LLC’s holdings in Johnson & Johnson were worth $10,147,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Keener Financial Planning LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at approximately $40,000. WFA Asset Management Corp grew its holdings in Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares in the last quarter. Disciplined Equity Management Inc. purchased a new position in Johnson & Johnson during the 4th quarter valued at approximately $45,000. Altshuler Shaham Ltd lifted its stake in shares of Johnson & Johnson by 37.8% in the 3rd quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock valued at $49,000 after purchasing an additional 87 shares during the last quarter. Finally, Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $61,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.0 %

Shares of NYSE:JNJ traded up $0.07 on Wednesday, reaching $144.45. The company had a trading volume of 8,262,698 shares, compared to its average volume of 7,416,246. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The firm’s 50 day simple moving average is $150.88 and its 200-day simple moving average is $155.08. The firm has a market capitalization of $347.64 billion, a PE ratio of 9.00, a PEG ratio of 2.44 and a beta of 0.55. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same period last year, the business posted $2.68 EPS. The business’s revenue was up 2.3% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 10.64 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.43%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s payout ratio is 30.92%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on JNJ shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, May 22nd. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, May 6th. Finally, Bank of America decreased their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $175.86.

Get Our Latest Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.